When it comes to taking Cerezyme, its maker doesn’t always take “no” for an answer. Dr. Peter A. Kouides, a hematologist at Rochester General Hospital, said he once had a patient with Gaucher disease who declined to be treated with Cerezyme, a drug made by Genzyme. For years, he said, Genzyme’s representatives “were always bugging us about why we weren’t treating this guy.”
“If I decide not to treat someone, that’s too bad for Genzyme,” said one of them, Dr. Barry E. Rosenbloom, who runs the big Gaucher center in the Los Angeles area. Dr. Rosenbloom said his center gets $150,000 a year from Genzyme to pay for one full-time person and one half-time person, in part to contribute data to a patient registry.
Drug Maker Stays Close to Doctors and Patients - New York Times
0 comments :
Post a Comment